Capitolis Liquid Global Markets LLC Purchases 75,000 Shares of Boston Scientific Corporation $BSX

Capitolis Liquid Global Markets LLC increased its position in Boston Scientific Corporation (NYSE:BSX) by 46.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 235,000 shares of the medical equipment provider’s stock after buying an additional 75,000 shares during the period. Capitolis Liquid Global Markets LLC’s holdings in Boston Scientific were worth $22,943,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. Steph & Co. bought a new stake in Boston Scientific in the third quarter worth approximately $25,000. Financial Consulate Inc. acquired a new position in shares of Boston Scientific during the 3rd quarter worth $25,000. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the 2nd quarter valued at $26,000. Finally, United Community Bank lifted its stake in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on BSX. UBS Group decreased their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, February 5th. JPMorgan Chase & Co. reduced their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a report on Friday, February 6th. Finally, Citigroup cut their price objective on Boston Scientific from $102.00 to $94.00 and set a “buy” rating on the stock in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.00.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Boston Scientific Price Performance

NYSE:BSX opened at $69.15 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific Corporation has a one year low of $67.56 and a one year high of $109.50. The company has a fifty day moving average price of $82.47 and a 200 day moving average price of $93.29. The stock has a market cap of $102.61 billion, a P/E ratio of 35.64, a PEG ratio of 0.97 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the business posted $0.70 EPS. The business’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.